B-
BiotechTV - News
STIFEL 2026: Cullinan Therapeutics' CEO Nadim Ahmed gives an overview of the progress of the company's T-cell engagers in autoimmune and oncology (and more)
0:00-11:24
He goes over a partner's BCMA data that was just presented this weekend at ACR in lupus, and previews a key CD19 update that Cullinan will be providing investors in December. Plus, he comments on zipalertinib, which is in front of FDA now in two lines of therapy.
Publisher
BiotechTV - News
Link
podcasters.spotify.com/pod/show/biotechtv4/episodes/STIFEL-2026-Cullinan-Therapeutics-CEO-Nadim-Ahmed-gives-an-overview-of-the-progress-of-the-companys-T-cell-engagers-in-autoimmune-and-oncology-and-more-e3s6aqg
Published
November 11, 2026
Duration
11 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BiotechTV
B-
BiotechTV - News
@biotechtvnews
#cullinantherapeuticsceo #cellengagers #autoimmune #lifesciences
